Clinical

Clinical  ·  Weekly Digest - 28 February to 06 March 2026
PADCEV + Keytruda cuts risk of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer

Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: PADCEV + Keytruda cuts risk of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer Pfizer and Astellas Pharma reported strong Phase 3 results for […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 28 February to 06 March 2026
Henlius doses first patient in phase 2/3 trial of anti-HER2 mAb HLX22 in combination with anti-HER2 ADC HLX87 for first-line treatment of HER2-positive breast cancer

Weekly Digest – March 2026 Weekly Digest – March 2026 28 February 2026: Henlius doses first patient in phase 2/3 trial of anti-HER2 mAb HLX22 in combination with anti-HER2 ADC HLX87 for first-line treatment of HER2-positive breast cancer Shanghai Henlius […]

by Sandhya Ramalingam

Continue Reading